The inhaled insulin is as effective as subcutaneous injection
Inhaled insulin appears to provide glycemic control comparable to that achieved by subcutaneous injection in patients with type 2 diabetes, a new study. A study published in Diabetes Care at random 107 patients with a mean age of 59 years and an average 2 diabetes duration of 12 years for inhaled insulin or taking insulin subcutaneously. The group uses the inhaler of rapid-acting insulin human immediately before meals, as the subcutaneous group and both groups were injected subcutaneously at bedtime NPH insulin.At the end of 12 weeks in the open, no significant difference in HbA1c between groups. However, fasting glucose was significantly lower in the inhaler group (8.9 mmol / L) than in the subcutaneous group (10.8 mmol / L). The incidence of adverse events was similar in
both groups and no significant safety issue. The authors conclude that it is used before meals, the system of inhaled insulin is as effective as subcutaneous injection for glycemic control. They add that more studies are needed to examine in particular the long-term security of the system.Reference: Hermansen K et al (2003) Intensive therapy with inhaled insulin via the AERx insulin system of control of diabetes: A 12-week proof of concept study in patients with type 2 diabetes, Diabetes Care 27 (1) 162-167